You are here: Industry Insights > AstraZeneca

News List

FDA approves AstraZeneca’s faslodex for expanded use in breast cancer pharmaceutical-technology
August 31, 2017
AstraZeneca’s faslodex (fulvestrant) at 500mg has received approval from the US Food and Drug Administration (FDA) as monotherapy for expanded use in women with advanced breast cancer.
AstraZeneca oldie Faslodex nets another breast cancer approval fiercepharma
August 30, 2017
AstraZeneca's Faslodex won its first approval back in 2002.
AstraZeneca unloads another drug for $400m pharmafile
August 30, 2017
AstraZeneca has had to do a serious re-think of its portfolio post-Mystic failure and it has made another move to raise cash, whilst still keeping an eye on development progress.
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's worldpharmanews
August 30, 2017
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341
Berg work with AstraZeneca to identify new therapeutic targets to treat neurological disorders cphi-online
August 30, 2017
Collaboration to focus on a disease target in Parkinson's disease.
Astrazeneca, Takeda Establish Collaboration to Develop, Commercialize MEDI1341 americanpharmaceuticalreview
August 30, 2017
AstraZeneca and Takeda have entered an agreement to jointly develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC fiercepharma
August 25, 2017
In a new analysis of older trial data, Brilinta showed it could cut the risk of cardiovascular death by 29% compared with placebo.
Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk pharmafile
August 25, 2017
New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk of heart attacks by almost a third in patients with a history of such atherothrombotic events.
Aspen Pharmacare Completes Transfer of AstraZeneca's Anesthetic Medicines Portfolio americanpharmaceuticalreview
August 25, 2017
On Friday, August 18, 2017, Aspen Pharmacare Canada officially completed the transfer of Canadian commercialization rights associated with five of AstraZeneca's anesthetic products.
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with histor worldpharmanews
August 25, 2017
AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page